A Repeatability and Reproducibility Study of the EarliPoint™ Device

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-07

Study Completion Date

2021-11-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a prospective randomized repeatability and reproducibility (R\&R) study of the EarliPoint DeviceTM in pediatric subjects 16-30 months of age. The study will enroll subjects who are both clinically-positive and clinically-negative for ASD.

The study will be conducted at a single center in the US. The Study consists of a screening period in order to review the subject's medical history to determine subject eligibility, followed by a device administration period during which subjects will undergo testing with the EarliPoint Devices and Expert Clinician Diagnosis (ECD) procedures to determine if they are clinically-positive or clinically-negative for ASD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

NCT05675371

Autism Spectrum Disorder Autism Developmental Delay +2 more

COMPLETED

Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement

NCT05916430

Autism Infant Development

RECRUITING

Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD)

NCT05806216

Autism Spectrum Disorder Autism

COMPLETED

Screening for Autism Spectrum Disorders Using Auditory Brainstem Responses

NCT03971578

Autism Spectrum Disorder

COMPLETED

Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder

NCT04600882

Autism Spectrum Disorder

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will undergo testing with the same two (2) devices, with one (1) testing session per device per subject, with each testing session yielding three (3) measurements per endpoint per subject, for a total of six (6) measurements per endpoint for each subject enrolled. The order in which the subjects receive testing with each device will be randomized so that the same device is not always used first or last for each subject.

The primary objectives of this study are to quantify the repeatability variability and reproducibility variability of all of the EarliPoint device's continuous valued outputs: the underlying continuous score used to classify patients into the binary diagnostic classification of either clinically-positive or clinically-negative for autism spectrum disorder (ASD) as well as each of the three EarliPoint Device severity scores (the social disability index, verbal ability index, and nonverbal ability index).

The secondary objectives of this study are to quantify the repeatability and reproducibility variability in producing each of the three EarliPoint Device severity scores: the social disability index, verbal ability index, and nonverbal ability index.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder (ASD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EarliPoint

EarliPoint is a non-invasive diagnostic device for ASD

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children between 16 and 30 months of age.
* No acute illnesses by physical observation.
* Normal or corrected-to-normal vision, and normal or corrected-to-normal hearing.
* Communicate meaningfully with patent in English, and the principal investigator /the study team.
* Parent or legal guardian is able to read and understand the Informed Consent Form.
* Parent voluntarily provides written informed consent.

Exclusion Criteria

* Genetic disorders (e.g., Fragile X, Williams Syndrome, Tuberous Sclerosis, muscular Dystrophy, Neurofibromatosis, Down Syndrome).
* History or presence of a clinically significant medical disease or a mental state that might confound the study result as assessed by the investigator, such as severe hearing or visual impairment; or uncontrolled epilepsy or seizure disorder, et al.
* Acute exacerbations of chronic illnesses likely to prevent successful data collection.
* Receiving therapies that may affect vision.
* Therapies that may affect the ability to focus.
* Known allergies or sensitivity to the plastic, leather, or metal components.
* Unable or unwilling to sit in a child safety seat.
* Use of any investigational drug, therapies or diagnostic device within the past 14 days.

Minimum Eligible Age

16 Months

Maximum Eligible Age

30 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No